1. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007;187(7 Suppl):S8-S10. PMID:
17908033.
2. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry 2008;7:148-156. PMID:
18836582.
3. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005;162:1785-1804. PMID:
16199825.
4. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005;79:85-93. PMID:
16005612.
5. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005;62:975-983. PMID:
16143729.
6. Norman RM, Lewis SW, Marshall M. Duration of untreated psychosis and its relationship to clinical outcome. Br J Psychiatry Suppl 2005;48:S19-S23. PMID:
16055802.
7. Chang WC, Hui CL, Tang JY, Wong GH, Chan SK, Lee EH, et al. Impacts of duration of untreated psychosis on cognition and negative symptoms in first-episode schizophrenia: a 3-year prospective follow-up study. Psychol Med 2013;43:1883-1893. PMID:
23217676.
8. Tang JY, Chang WC, Hui CL, Wong GH, Chan SK, Lee EH, et al. Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study. Schizophr Res 2014;153:1-8. PMID:
24529612.
9. Compton MT, Chien VH, Leiner AS, Goulding SM, Weiss PS. Mode of onset of psychosis and family involvement in help-seeking as determinants of duration of untreated psychosis. Soc Psychiatry Psychiatr Epidemiol 2008;43:975-982. PMID:
18604616.
10. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998;172:53-59. PMID:
9764127.
11. McGorry PD. The recognition and optimal management of early psychosis: an evidence-based reform. World Psychiatry 2002;1:76-83. PMID:
16946857.
12. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management (Clinical guideline 178) Accessed Feb, 2014. Available:
http://guidance.nice.org.uk/CG178.
13. Tarrier N, Haddock G, Barrowclough C, Wykes T. Are all psychological treatments for psychosis equal? The need for CBT in the treatment of psychosis and not for psychodynamic psychotherapy. Psychol Psychother 2002;75:365-374. PMID:
12626130.
14. Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kindrman P, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br J Psychiatry 2004;184:231-239. PMID:
14990521.
15. Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res 2005;77:1-9. PMID:
16005380.
16. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008;34:523-537. PMID:
17962231.
17. Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol 2013;9:465-497. PMID:
23330939.
18. Lecomte T, Leclerc C, Corbière M, Wykes T, Wallace CJ, Spidel A. Group cognitive behavior therapy or social skills training for individuals with a recent onset of psychosis? Results of a randomized controlled trial. J Nerv Ment Dis 2008;196:866-875. PMID:
19077853.
19. Lecomte T, Leclerc C, Wykes T. Group CBT for early psychosis--are there still benefits one year later? Int J Group Psychother 2012;62:309-321. PMID:
22468576.
20. Chung YC, Yoon KS, Park TW, Yang JC, Oh KY. Group cognitive-behavioral therapy for early psychosis. Cognit Ther Res 2013;37:403-411.
21. Moritz S, Vitzthum F, Randjbar S, Veckenstedt R, Woodward TS. Detecting and defusing cognitive traps: metacognitive intervention in schizophrenia. Curr Opin Psychiatry 2010;23:561-569. PMID:
20683332.
22. Vitzthum FB, Veckenstedt R, Moritz S. Individualized metacognitive therapy program for patients with psychosis (MCT+): introduction of a novel approach for psychotic symptoms. Behav Cogn Psychother 2014;42:105-110. PMID:
23631928.
23. Moritz S, Veckenstedt R, Bohn F, Hottenrott B, Scheu F, Randjbar S. Complementary group Metacognitive Training (MCT) reduces delusional ideation in schizophrenia. Schizophr Res 2013;151:61-69. PMID:
24183707.
24. Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, et al. Sustained and “sleeper” effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiatry 2014;71:1103-1111. PMID:
25103718.
25. Beck AT, Rector NA. Cognitive approaches to schizophrenia: theory and therapy. Annu Rev Clin Psychol 2005;1:577-606. PMID:
17716100.
27. Kim SW, Lee GY, Yu HY, Jung EI, Lee JY, Kim SY, et al. Development and feasibility of smartphone application for cognitive behavioral case management of individuals with early psychosis. Early Interv Psychiatry In press [Epub ahead of print].
28. Lee GY, Yu HY, Jhon M, Yoon JS, Kim SW. Intensive cognitive behavioral case management for functional recovery of young patients with schizophrenia. Korean J Schizophr Res 2016;19:32-37.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th Ed. Arlington, VA: American Psychiatric Publishing; 2013.
30. Naber D, Mortiz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88. PMID:
11378316.
31. Kim SW, Shin IS, Kim JM, Yoo JA, Ahn YM, Kwon JS, et al. A validation study of the Korean version of Subjective Well-being under Neuroleptic Treatment Scale-short form. Korean J Psychopharmacol 2007;18:221-230.
32. Combs DR, Penn DL, Wicher M, Waldheter E. The Ambiguous Intentions Hostility Questionnaire (AIHQ): a new measure for evaluating hostile social-cognitive biases in paranoia. Cogn Neuropsychiatry 2007;12:128-143. PMID:
17453895.
33. Chang H, Lee SK, Kim KR, Lee SY, Park JY, Kim EJ, et al. Development of Korean version of the Ambiguous Intentions Hostility Questionnaire (K-AIHQ). J Korean Neuropsychiatr Assoc 2009;48:29-35.
34. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-183. PMID:
6133297.
35. Yoon BH, Bahk WM, Lee KU, Hong CH, Ahn JK, Kim MK. Psychometric properties of Korean version of Drug Attitude Inventory (KDAI-10). Korean J Psychopharmacol 2005;16:480-487.
36. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571. PMID:
13688369.
37. Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ. Standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc 1986;25:487-502.
38. Cohen S, Williams G. Perceived Stress in a Probability Sample of the United States. In: Spacapan S, Oskamp S, editor. The Social Psychology of Health. Thousand Oaks, CA, US: Sage Publications, Inc, 1988, p. 31-67.
39. Lee J, Shin C, Ko YH, Lim JH, Joe SH, Kim SH, et al. The reliability and validity studies of the Korean version of the Perceived Stress Scale. Korean J Psychosom Med 2012;20:127-134.
40. Guy W. CGI Clinical Global Impressions. In ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville MD: US Department of Mental Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1976, p. 217-222.
41. An SK, Kang JI, Park JY, Kim KR, Lee SY, Lee E. Attribution bias in ultra-high risk for psychosis and first-episode schizophrenia. Schizophr Res 2010;118:54-61. PMID:
20171849.
42. Combs DR, Penn DL, Michael CO, Basso MR, Weideman R, Siebenmorgan M, et al. Perceptions of hostility with and without persecutory delusions. Cogn Neuropsychiatry 2009;14:30-52. PMID:
19214841.
43. Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, et al. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 2016;173:362-372. PMID:
26481174.
44. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
45. Ussorio D, Giusti L, Wittekind CE, Bianchini V, Malavolta M, Pollice R, et al. Metacognitive training for young subjects (MCT young version) in the early stages of psychosis: is the duration of untreated psychosis a limiting factor? Psychol Psychother 2016;89:50-65. PMID:
25799999.
46. Naeem F, Kingdon D, Turkington D. Predictors of response to cognitive behavior therapy in the treatment of schizophrenia: a comparison of brief and standard interventions. Cognit Ther Res 2008;32:651-656.
48. Garety P, Fowler D, Kuipers E, Freeman D, Dunn G, Bebbington P, et al. London-East Anglia randomised controlled trial of cognitive-behaviour therapy for psychosis. II: Predictors of outcome. Br J Psychiatry 1997;171:420-426. PMID:
9463599.
49. Menon M, Andersen DR, Quilty LC, Woodward TS. Individual factors predicted to influence outcome in group CBT for psychosis (CBTp) and related therapies. Front Psychol 2015;6:1563PMID:
26578995.
50. Beauchamp MC, Lecomte T, Lecomte C, Leclerc C, Corbière M. Do personality traits matter when choosing a group therapy for early psychosis? Psychol Psychother 2013;86:19-32. PMID:
23386553.
51. Uçok A, Polat A, Genç A, Cakir S, Turan N. Duration of untreated psychosis may predict acute treatment response in first-episode schizophrenia. J Psychiatr Res 2004;38:163-168. PMID:
14757330.
52. Perkins D, Lieberman J, Gu H, Tohen M, McEvoy J, Green A, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004;185:18-24. PMID:
15231551.
53. Rangaswamy T, Mangala R, Mohan G, Joseph J, John S. Intervention for first episode psychosis in India-The SCARF experience. Asian J Psychiatr 2012;5:58-62. PMID:
26878950.
54. Marshall M, Husain N, Bork N, Chaudhry IB, Lester H, Everard L, et al. Impact of early intervention services on duration of untreated psychosis: data from the National EDEN prospective cohort study. Schizophr Res 2014;159:1-6. PMID:
25107851.
55. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2014;205:88-94. PMID:
25252316.
56. Lappin JM, Morgan KD, Morgan C, Dazzan P, Reichenberg A, Zanelli JW, et al. Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophr Res 2007;95:103-110. PMID:
17644343.
57. Malla AK, Norman RM, Manchanda R, Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 2002;32:1109-1119. PMID:
12214790.
58. Alvarez-Jiménez M, Gleeson JF, Cotton S, Wade D, Gee D, Pearce T, et al. Predictors of adherence to cognitive-behavioural therapy in first-episode psychosis. Can J Psychiatry 2009;54:710-718. PMID:
19835678.
59. Addington J, Heinssen RK, Robinson DG, Schooler NR, Marcy P, Brunette MF, et al. Duration of Untreated Psychosis in Community Treatment Settings in the United States. Psychiatr Serv 2015;66:753-756. PMID:
25588418.
60. Alvarez-Jimenez M, Gleeson JF, Henry LP, Harrigan SM, Harris MG, Amminger GP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 2011;125:236-246. PMID:
21081266.
61. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl 2005;48:S116-S119. PMID:
16055800.
62. Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P. Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 2008;42:982-990. PMID:
18199456.
63. Moritz S, Krausz M, Gottwalz E, Lambert M, Perro C, Ganzer S, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000;33:48-51. PMID:
10601828.
64. Naber D. A self-rating to measure subjective effects of neuroleptic drug relationships to objective psychopathology, quality of life, compliance, and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl 3):133-138. PMID:
8866775.
65. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005;38:320-326. PMID:
16224206.
66. Wehmeier PM, Kluge M, Schneider E, Schacht A, Wagner T, Schreiber W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:703-712. PMID:
17289237.
67. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second-versus first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087. PMID:
17015810.
68. Lambert M, Naber D, Eich FX, Schacht M, Linden M, Schimmelmann BG. Remission of severely impaired subjective well-being in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007;115:106-113. PMID:
17244174.
69. Kim SW, Yoon JS, Kim YS, Ahn YM, Kim CE, Go HJ, et al. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:228-235. PMID:
22516251.
70. Karow A, Naber D, Lambert M, Moritz S. EGOFORS Initiative. Remission as perceived by people with schizophrenia, family members and psychiatrists. Eur Psychiatry 2012;27:426-431. PMID:
21571506.
71. Rossi A, Vita A, Tiradritti P, Romeo F. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 2008;23:216-222. PMID:
18545060.